Keyphrases
Meta-analysis
100%
Success Rate
100%
Therapeutic Outcome
100%
Phase II Trial
100%
Predictive Success
100%
Biologic Therapy
100%
Clinical Equipoise
100%
Odds Ratio
28%
Randomized Controlled Trial
28%
Hazard Ratio
28%
Standard of Care
28%
Progression-free Survival
28%
Selected Populations
28%
Treatment Efficacy
14%
Lung Cancer
14%
Survival Benefit
14%
Relative Reduction
14%
Overall Survival
14%
Rapid Access
14%
Disease Progression
14%
Potential Biomarkers
14%
Advanced Prostate Cancer
14%
Overall Survival Benefit
14%
Ethical Requirements
14%
Advanced Breast Cancer
14%
Advanced Colorectal Cancer
14%
Predictive Biomarker
14%
Scientific Requirements
14%
Pharmacology, Toxicology and Pharmaceutical Science
Phase III Trials
100%
Biological Product
100%
Biological Marker
66%
Randomized Controlled Trial
33%
Overall Survival
33%
Progression Free Survival
33%
Lung Cancer
16%
Combination Therapy
16%
Breast Cancer
16%
Prostate Cancer
16%
Colorectal Carcinoma
16%
Disease Exacerbation
16%
Phase II Trials
16%